Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CLYMNASDAQ:KALANYSE:VORNASDAQ:ZNTL On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCLYMClimb Bio$1.30-4.8%$1.36$1.05▼$11.55$87.38M-0.1334,797 shs6,357 shsKALAKALA BIO$3.58+1.4%$6.39$3.35▼$11.20$23.10M-1.7186,540 shs2,319 shsVORVor Biopharma$0.67-3.7%$0.94$0.49▼$1.95$84.15M-0.21584,607 shs47,677 shsZNTLZentalis Pharmaceuticals$1.27-0.4%$1.80$1.01▼$13.46$90.84M1.81.53 million shs294,683 shs7 AI Stocks to Invest in Today: Capitalizing on AI and Tech Trends in 2025Discover the top 7 AI stocks to invest in right now. This exclusive report highlights the companies leading the AI revolution and shaping the future of technology in 2025.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCLYMClimb Bio+3.82%+20.35%+0.74%-32.00%+135,999,900.00%KALAKALA BIO+1.15%+0.86%-46.11%-50.49%-49.57%VORVor Biopharma+1.30%+27.27%-21.83%-48.91%-61.11%ZNTLZentalis Pharmaceuticals+4.10%+22.12%-28.25%-55.44%-90.43%Remove AdsCompare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCLYMClimb Bio3.1786 of 5 stars3.80.00.00.03.32.51.3KALAKALA BIO3.5847 of 5 stars3.52.00.04.42.70.00.6VORVor Biopharma1.646 of 5 stars3.50.00.00.00.02.50.6ZNTLZentalis Pharmaceuticals2.5905 of 5 stars3.24.00.00.02.71.70.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCLYMClimb Bio 3.50Strong Buy$10.00672.20% UpsideKALAKALA BIO 3.00Buy$15.00318.99% UpsideVORVor Biopharma 3.00Buy$8.861,214.12% UpsideZNTLZentalis Pharmaceuticals 2.44Hold$8.24551.73% UpsideCurrent Analyst Ratings BreakdownLatest KALA, CLYM, ZNTL, and VOR Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/4/2025KALAKALA BIOHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$15.00 ➝ $15.003/28/2025ZNTLZentalis PharmaceuticalsWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral ➝ Neutral$4.00 ➝ $4.003/27/2025ZNTLZentalis PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$10.00 ➝ $10.003/21/2025VORVor BiopharmaOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$8.00 ➝ $8.003/21/2025VORVor BiopharmaHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$17.50 ➝ $13.003/21/2025VORVor BiopharmaStifel NicolausSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$12.00 ➝ $5.003/20/2025VORVor BiopharmaWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform$7.003/17/2025ZNTLZentalis PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$10.00 ➝ $10.002/13/2025KALAKALA BIOHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$15.00 ➝ $15.001/30/2025ZNTLZentalis PharmaceuticalsWells Fargo & CompanySubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetEqual Weight ➝ Equal Weight$8.00 ➝ $6.001/29/2025ZNTLZentalis PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$20.00 ➝ $10.00(Data available from 4/16/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCLYMClimb BioN/AN/AN/AN/A$3.90 per shareN/AKALAKALA BIO$3.89M5.94N/AN/A$2.79 per share1.28VORVor BiopharmaN/AN/AN/AN/AN/AN/AZNTLZentalis Pharmaceuticals$67.43M1.35N/AN/A$6.18 per share0.20Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCLYMClimb Bio-$35.12M-$2.13N/AN/AN/AN/A-42.21%-41.39%5/21/2025 (Estimated)KALAKALA BIO-$42.20M-$11.03N/AN/AN/AN/A-448.61%-69.37%5/13/2025 (Estimated)VORVor BiopharmaN/A-$1.70N/AN/AN/AN/AN/AN/AN/AZNTLZentalis Pharmaceuticals-$292.19M-$2.32N/AN/AN/AN/A-43.91%-34.96%5/6/2025 (Estimated)Latest KALA, CLYM, ZNTL, and VOR EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/13/2025Q1 2025KALAKALA BIO-$2.03N/AN/AN/AN/AN/A5/6/2025N/AZNTLZentalis Pharmaceuticals-$0.70N/AN/AN/AN/AN/A3/28/2025Q4 2024KALAKALA BIO-$2.28-$1.74+$0.54-$1.74N/AN/A3/26/2025Q4 2024ZNTLZentalis Pharmaceuticals-$0.75-$0.66+$0.09-$0.66N/A$26.90 million3/25/2025Q4 2024CLYMClimb Bio-$0.15-$0.13+$0.02-$0.13N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCLYMClimb BioN/AN/AN/AN/AN/AKALAKALA BION/AN/AN/AN/AN/AVORVor BiopharmaN/AN/AN/AN/AN/AZNTLZentalis PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCLYMClimb BioN/A57.7357.73KALAKALA BIO3.182.152.15VORVor BiopharmaN/AN/AN/AZNTLZentalis PharmaceuticalsN/A7.297.29Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCLYMClimb Bio69.76%KALAKALA BIO24.61%VORVor Biopharma97.29%ZNTLZentalis PharmaceuticalsN/AInsider OwnershipCompanyInsider OwnershipCLYMClimb Bio3.20%KALAKALA BIO8.32%VORVor Biopharma4.70%ZNTLZentalis Pharmaceuticals3.60%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCLYMClimb Bio967.48 million65.07 millionN/AKALAKALA BIO306.45 million5.58 millionNot OptionableVORVor Biopharma140124.85 million65.45 millionNot OptionableZNTLZentalis Pharmaceuticals16071.81 million68.70 millionOptionableKALA, CLYM, ZNTL, and VOR HeadlinesRecent News About These CompaniesWhy Zentalis Pharmaceuticals, Inc.’s (ZNTL) Stock Is Down 8.97%April 10, 2025 | aaii.comBrokerages Set Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Target Price at $8.24April 6, 2025 | americanbankingnews.comZentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Given Average Rating of "Hold" by BrokeragesApril 4, 2025 | marketbeat.comWhy Zentalis Pharmaceuticals, Inc.’s (ZNTL) Stock Is Down 12.58%April 2, 2025 | aaii.comZentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)April 1, 2025 | globenewswire.comWhat is HC Wainwright's Forecast for ZNTL Q1 Earnings?March 31, 2025 | marketbeat.comLeerink Partnrs Has Pessimistic Outlook of ZNTL Q1 EarningsMarch 31, 2025 | marketbeat.comWedbush Reaffirms Neutral Rating for Zentalis Pharmaceuticals (NASDAQ:ZNTL)March 29, 2025 | marketbeat.comZentalis Pharmaceuticals (NASDAQ:ZNTL) Posts Earnings Results, Beats Expectations By $0.09 EPSMarch 28, 2025 | marketbeat.comHC Wainwright Reaffirms Buy Rating for Zentalis Pharmaceuticals (NASDAQ:ZNTL)March 28, 2025 | marketbeat.comStifel Nicolaus Sticks to Their Buy Rating for Zentalis Pharmaceuticals (ZNTL)March 27, 2025 | markets.businessinsider.comZentalis Pharmaceuticals Reports Full Year 2024 Financial Results and Operational UpdatesMarch 26, 2025 | globenewswire.comZentalis Pharmaceuticals to Present Multiple Posters at the American Association for Cancer Research (AACR) Annual Meeting 2025March 25, 2025 | globenewswire.comZentalis Pharmaceuticals' (ZNTL) "Buy" Rating Reaffirmed at HC WainwrightMarch 18, 2025 | marketbeat.comZentalis presents updated clinical data on azenosertib as SGO 2025March 16, 2025 | markets.businessinsider.comZentalis Pharmaceuticals Presents Updated Clinical Data at the Society of Gynecologic Oncology 2025 Annual Meeting on Women’s CancerMarch 15, 2025 | finance.yahoo.comZentalis Pharmaceuticals Presents Updated Clinical Data at the Society of Gynecologic Oncology 2025 Annual Meeting on Women's CancerMarch 15, 2025 | globenewswire.comZentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)March 3, 2025 | globenewswire.comZentalis Pharmaceuticals Announces Multiple Data Presentations at Society of Gynecologic Oncology 2025 Annual Meeting on Women’s CancerMarch 3, 2025 | markets.businessinsider.comZentalis Pharmaceuticals Announces Multiple Data Presentations at Society of Gynecologic Oncology 2025 Annual Meeting on Women's CancerMarch 3, 2025 | globenewswire.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zentalis Pharmaceuticals, Inc. - ZNTLMarch 1, 2025 | accessnewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeKALA, CLYM, ZNTL, and VOR Company DescriptionsClimb Bio NASDAQ:CLYM$1.30 -0.07 (-4.78%) As of 11:09 AM EasternClimb Bio Inc. is a clinical-stage biotechnology company developing therapeutics for patients with immune-mediated diseases. The Company's lead product candidate, budoprutug, is an anti-CD19 monoclonal antibody which has demonstrated B-cell depletion and has potential to treat a broad range of B-cell mediated diseases. Climb Bio Inc., formerly known as Eliem Therapeutics Inc., is based in WELLESLEY, Mass.KALA BIO NASDAQ:KALA$3.58 +0.05 (+1.42%) As of 11:41 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.KALA BIO, Inc., a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of innovative therapies for rare and severe eye diseases in the United States. The company's product candidates include KPI-012, which is in Phase 2b clinical trial for the treatment of persistent corneal epithelial defects. Its preclinical development product, including KPI-014 for the treatment of rare inherited retinal diseases. The company was formerly known as Kala Pharmaceuticals, Inc. and changed its name to KALA BIO, Inc. in August 2023. KALA BIO, Inc. was incorporated in 2009 and is headquartered in Arlington, Massachusetts.Vor Biopharma NYSE:VOR$0.67 -0.03 (-3.71%) As of 11:46 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Vor Biopharma Inc. operates as a clinical-stage cell and genome engineering company. Its lead product is tremtelectogene empogeditemcel (trem-cel), an engineered hematopoietic stem cell (eHSC) product candidate that is in phase 1/2 trial to treat acute myeloid leukemia (AML) and other hematological malignancies. The company is also developing Mylotarg, a CD33-directed antibody drug conjugate (ADC) therapy for patients with leukemia; VCAR33, a CAR-T therapy designed to target CD33, a clinically validated target for AML, which are under preclinical and Phase 1/2 clinical studies; trem-cel + VCAR33 treatment system that is under preclinical studies for the treatment of AML; and CD33-CLL1 treatment system made with CD33-CLL1 multiplex-engineered eHSC and CD33-CLL1 multi-specific CAR-T, which are under preclinical studies for the treatment of AML. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.Zentalis Pharmaceuticals NASDAQ:ZNTL$1.26 -0.01 (-0.39%) As of 11:46 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer. The company's products pipeline also includes ZN-d5, an oral small molecule inhibitor of B-cell lymphoma 2, for hematological malignancies and related disorders; and BCL-xL heterobifunctional degrader, a member of the anti-apoptotic BCL-2 proteins, for solid tumors and hematological malignancies. Zentalis Pharmaceuticals, Inc. has licensing agreements and strategic collaborations with Recurium IP Holdings, LLC; Pfizer, Inc.; Zentera Therapeutics; Dana-Farber; and GlaxoSmithKline plc. The company was incorporated in 2014 and is headquartered in New York, New York. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Tesla Stock Eyes Breakout With Earnings on Deck Qualcomm Stock Just Earned a Fresh Buy Rating—Get Excited Viking Therapeutics Stock Pops But Struggles to Hold Gains Johnson & Johnson Earnings Were More Good Than Bad—Time to Buy? CrowdStrike Stock is a Buy as Cyberthreat Environment Expands Lemonade: Leveraging AI to Underwrite a Path to Profitability 2 Penny Stocks With $10 Potential Congress! Who Traded What During the Tariff-Induced Meltdown Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
